Alamar Biosciences, Inc. Common Stock

Day range

$30.01 – $31.24

Open

$30.65

Prev close

$30.69

Volume

320.48K

Market cap

$2.13B

Shares out

69.39M

• Director appointmentSep 1, 2026

  On August 28, 2026, the board of directors (the "Board") of Alamar Biosciences, Inc. (the "Company") appointed Robert Ragusa to the Board, effective as of September 1, 2026. Mr. Ragusa will serve as a Class I Director, with an initial term expiring at the Company's 2027 Annual Meeting of Stockholders. Mr. Ragusa was also appointed to the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee of the Board.

• Director departureJul 15, 2026

  Ian Ratcliffe, a member of the Company's board of directors (the "Board"), passed away on July 5, 2026. Mr. Ratcliffe served as an independent director on the Board since February 2024.

• Public offeringApr 20, 2026

  On April 20, 2026, the Company completed its IPO of an aggregate of 12,937,500 shares of common stock (which includes the exercise in full of the underwriters' option to purchase an additional 1,687,500 shares of common stock) at a price to the public of $17.00 per share. The aggregate gross proceeds from the IPO, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, was approximately $219.9 million.

Days to cover

4.3

Short interest

2.81M

Avg volume

661.42K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment
  positiveGlobeNewswire Inc.· Sep 24, 2026
• Alamar Biosciences 联合多所顶尖研究型大学推出全国性研究计划，推进神经退行性疾病血液生物标志物相关研究
  positiveGlobeNewswire Inc.· Jul 13, 2026
• Alamar Biosciences 與多間頂尖研究大學合作啟動全國計劃，旨在推動神經退行性疾病相關的血漿生物標記研究
  positiveGlobeNewswire Inc.· Jul 13, 2026
• Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
  positiveGlobeNewswire Inc.· Jul 13, 2026
• Alamar Biosciences 的 NULISA 數據將於 AAIC 2026 上超過 140 場科學簡報會中亮相，突顯基於血液的阿茲海默症生物標記剖析之最新進展
  positiveGlobeNewswire Inc.· Jul 10, 2026